Online citations, reference lists, and bibliographies.

Selective Inhibition Of Osteoclast Vacuolar H(+)-ATPase.

C. Farina, S. Gagliardi
Published 2002 · Chemistry, Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
The proton pump expressed on the plasma membrane of bone resorbing osteoclasts, and which mediates the acidification of the extracellular environment in resorption lacuna, belongs to the family of vacuolar H(+)-ATPases, which are enzymes ubiquitously distributed among all cells and are evolutionary conserved. These pumps have two functional domains: a peripherally associated cytoplasmatic section, and a proton channel composed of several subunits one of which, the 116 kDa subunit, is expressed exclusively in osteoclasts and confers unique functional and pharmacological properties to the osteoclast V-ATPase. It was demonstrated that inhibition of this pump can abolish bone resorption; therefore, osteoclast-selective inhibitors could provide novel and useful agents for the treatment of osteoporosis. This paper reviews the medicinal chemistry approaches that have allowed to obtain such new agents, most of which have been designed starting from the natural macrolide antibiotic bafilomycin A(1), a potent and selective inhibitor of all V-ATPases. Identification of SAR and of minimal structural requirements for bafilomycin activity have allowed to obtain (2Z,4E)-5-(5,6-dichloroindolyl)-2-methoxy-N-(1,2,2,6,6-pentamethylpiperidin-4-yl)-2,4-pentadienamide (SB-242784) which inhibits the osteoclastic proton pump and bone resorption in vitro. Although it inhibits the activity of non-osteoclastic proton pumps as well, it appears to have reasonable selectivity and its administration for 6 months prevented the loss of femoral and vertebral BMD in ovariectomized rats, without any significant renal effects in control and acid-loaded animals. Other independent approaches that did not start from bafilomycin have led to the discovery of a different class of V-ATPase inhibitors, among which 4-(2,6-dichlorobenzoyl)amino-2-trifluoromethyl(benzoimidazol-1-yl)acetyl morpholine (FR177995) was the most effective in preventing bone resorption in an ovariectomized rat model of osteoporosis. These compounds are of great pharmaceutical and medical interest because they allow to target a specific function of the osteoclast; however, only clinical trials might demonstrate whether they have significant advantages over other inhibitors of bone resorption for the treatment of osteoporosis.



This paper is referenced by
10.1529/BIOPHYSJ.107.111781
Interaction of spin-labeled inhibitors of the vacuolar H+-ATPase with the transmembrane Vo-sector.
Neil Dixon (2008)
10.1002/asia.201403299
Modification of bafilomycin structure to efficiently synthesize solid-state NMR probes that selectively bind to vacuolar-type ATPase.
H. Shibata (2015)
10.1016/j.ejcb.2012.04.004
pH regulators in invadosomal functioning: proton delivery for matrix tasting.
Lucie Brisson (2012)
10.1002/PHAR.1007
Fracture risk and bone mineral density reduction associated with proton pump inhibitors.
Yuen Ting Lau (2012)
ADAMs, OSTEOCLASTOGENESIS AND BONE DESTRUCTION IN THE LOOSENING OF THE TOTALLY REPLACED HIP
Guofeng Ma (2009)
PRELIMINARY STUDY IN VIVO OF THE BONE REGENERATIVE CAPACITY OF HYDROXYAPATITE WHEN ASSOCIATED WITH OMEPRAZOLE IN CRITICAL SIZE DEFECTS
Mariana do Souto Fontes Antunes Lopes (2012)
Atividade osteoclástica na superfície de hidroxiapatite nano e microestruturada modulada pela presença de inibidores da bomba de protões
Hélder Tiago Gomes Silva (2014)
Elucidating Vacuolar H+-ATPase Subunit Interactions: A Systematic Structural Analysis
Natoosha Natalie Nargaski (2015)
10.1007/s00223-012-9601-x
Pantoprazole, a Proton Pump Inhibitor, Delays Fracture Healing in Mice
T. Histing (2012)
10.1016/j.soard.2010.04.002
Bariatric surgery, proton pump inhibitors, and possibility of osteoporosis.
Mervyn Deitel (2010)
10.1517/14728222.7.3.453
The ATPases: a new family for a family-based drug design approach
Patrick Chène (2003)
10.1002/jbmr.3842
Increased risk of bone fractures in hemodialysis patients treated with proton pump inhibitors in real world: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS).
M. Fusaro (2019)
10.1016/J.MONRHU.2011.01.005
Ostéoporose et inhibiteurs de pompe à protons
Christian Roux (2011)
10.3164/jcbn.2008012
Proton Pump Inhibitors and Gastritis
Masayuki Suzuki (2008)
Anticancer effects of the V-ATPase inhibitor Archazolid B
Romina M. Wiedmann (2011)
10.1074/jbc.M110.167734
Enhanced Lysosomal Activity Is Involved in Bax Inhibitor-1-induced Regulation of the Endoplasmic Reticulum (ER) Stress Response and Cell Death against ER Stress
Geum-Hwa Lee (2011)
Effect of local delivery of HEBP and inorganic pyrophosphate on bone healing
Vanessa Cristina Mendes (2015)
10.1002/anie.200804645
Total synthesis of bafilomycin A1.
F. Kleinbeck (2009)
10.1001/archinternmed.2010.94
Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative.
S. Gray (2010)
Molecular biological, structural and functional analysis concerning the mechanism of membrane fusion in Paramecium cells
T. Wassmer (2005)
Un inhibiteur de la pompe à protons pour tous
Nicolas Morin (2010)
10.4081/ejh.2012.e43
Celecoxib treatment does not alter recruitment and activation of osteoclasts in the initial phase of experimental tooth movement
E.P. Carvalho-Filho (2012)
10.1002/EJOC.200901463
New Fluorous Photoaffinity Labels (F‐PAL) and Their Application in V‐ATPase Inhibition Studies
Nadja Burkard (2010)
Use of Synthetic Transporters to Facilitate Anion Transport across Vesicle and Cell Membranes
Beth A. McNally (2003)
10.22037/ghfbb.v1i3.33
Effect of omeprazole on bone mineral density and frequency of osteopenia and osteoporosis
Homayoun Zojaji (2009)
10.3949/ccjm.81a.13070
Do all hospitalized patients need stress ulcer prophylaxis?
Naseem Eisa (2014)
10.1016/J.REVMED.2011.12.011
Effets indésirables des inhibiteurs de la pompe à proton : faut-il craindre de les prescrire au long cours ?
Lucien Roulet (2012)
10.3892/IJMM_00000537
Effect of omeprazole on the expression of transcription factors in osteoclasts and osteoblasts.
J. Hyun (2010)
10.1111/dgd.12193
Vacuole dynamics in the salivary glands of Drosophila melanogaster during prepupal development.
Robert Farkaš (2015)
10.14670/HH-22.443
Structure and function of V-ATPases in osteoclasts: potential therapeutic targets for the treatment of osteolysis.
Jiake Xu (2007)
10.1186/ar2110
Cells of the synovium in rheumatoid arthritis. Osteoclasts
G. Schett (2007)
10.1002/9781444314403.CH16
16. Metabolic Bone Disease in Gastrointestinal Disorders
Ann Cranney (2010)
See more
Semantic Scholar Logo Some data provided by SemanticScholar